Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam
- 18 January 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in The European Journal of Health Economics
- Vol. 13 (2), 181-192
- https://doi.org/10.1007/s10198-011-0296-0
Abstract
Treating patients admitted to critical care with severe pneumonia requires timely intervention with an effective antibiotic. This reduces the risk of dying of pneumonia and minimises complications associated with a prolonged stay in critical care. To compare the cost-effectiveness of meropenem 1 g/8 h with piperacillin/tazobactam 4.5 g/8 h for treating pneumonia in UK critical care. A Markov model was built to estimate lifetime costs and quality-adjusted life years (QALYs) of using meropenem versus piperacillin/tazobactam to treat severe pneumonia. Estimates of effectiveness, utility weights and costs were obtained from published sources. Probabilistic sensitivity analysis was conducted to address uncertainty in the model results. Cost of treating a patient with severe pneumonia was estimated as £19,026 with meropenem and £19,978 with piperacillin/tazobactam, respectively. QALYs gained were 4.768 with meropenem and 4.654 with piperacillin/tazobactam. Probabilistic sensitivity analysis showed meropenem to be consistently less costly and more effective than piperacillin/tazobactam. The additional efficacy of meropenem translates into more patients surviving critical care and leaving this high-cost service more quickly than if they had been treated with piperacillin/tazobactam. As meropenem is more effective and less expensive than piperacillin/tazobactam at treating patients with severe pneumonia, it is the dominant treatment option.Keywords
This publication has 30 references indexed in Scilit:
- PIN73 CRITICAL CARE ADMISSIONS FOR PNEUMONIA IN ENGLANDValue in Health, 2009
- Indirect comparisons of treatments based on systematic reviews of randomised controlled trialsInternational Journal Of Clinical Practice, 2009
- Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparisonCurrent Medical Research and Opinion, 2008
- Deriving an Algorithm to Convert the Eight Mean SF-36 Dimension Scores into a Mean EQ-5D Preference-Based Score from Published Studies (Where Patient Level Data Are Not Available)Value in Health, 2008
- Carbapenems versus other beta-lactams in treating severe infections in intensive care: a systematic review of randomised controlled trialsEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- New guidelines for the management of adult community-acquired pneumoniaCurrent Opinion in Infectious Diseases, 2007
- Nosocomial pneumonia in the ICU: A prospective cohort studyScandinavian Journal of Infectious Diseases, 2007
- Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive careThe European Journal of Health Economics, 2006
- Current Guidelines for the Treatment of Severe Pneumonia and SepsisChemotherapy, 2005
- Survival, morbidity, and quality of life after discharge from intensive careCritical Care Medicine, 2000